JenaValve’s Series C swells to nearly $100M for its TAVI implants that treat cardiovascular stenosis
Transcatheter aortic valve implantation is a promising next-gen technology for common conditions like aortic stenosis. Irvine-based JenaValve Technology just added another $26.5 million to its Series C round, bringing the devicemaker to nearly $100 million for the round for its TAVI prosthetic valve.